A fine mapping study of the MHC region in a Swedish case-control population sample reported a novel type 1 diabetes (T1D) association from the inositol 1-, 4-, 5-trisphosphate receptor type 3 gene (ITPR3) in a case-control study, reportedly independent of the HLA class II effect. We attempted to replicate this novel association in a family-based study of 1120 T1D families with at least one affected child, an approach immune to population stratification. We found association of the ITPR3 single nucleotide polymorphisms (SNPs) rs2296336 with T1D but in a direction opposite to that reported. Moreover, rs2296336 was in linkage disequilibrium (LD) with specific alleles of the HLA DQB1 gene. Conditional regression showed that all of the ITPR3 SNP T1D association could be accounted for by the DQB1 effect. Therefore, our findings do not support an obvious role of genetic variation of the ITPR3 gene in T1D risk.
Introduction
Recently, a fine mapping study of the HLA region reported one novel type 1 diabetes (T1D) association with rs2296336, an intronic single-nucleotide polymorphism (SNP) of inositol 1-, 4-, 5-trisphosphate receptor type 3 (ITPR3), encoding the ITPR3 (P ¼ 1.30 Â 10
À6
) in a casecontrol study of 1124 Swedish individuals 1 . The ITPR3 protein is involved in regulating both insulin and pancreatic exocrine secretion, presumably through mediating Ca 2 þ mobilization 2, 3 and is, therefore, a good functional candidate.
ITPR3 (MIM:147267) maps to Chr6p21, B500 kb centrometric to the HLA class II genes DQ and DR, which confer the strongest known genetic risk for T1D. Because of the extended linkage disequilibrium (LD) in that region (Supplementary Figure 1S) , it is important to demonstrate independence of any observed effect from HLA class II. In a study by Roach et al., 1 the effect of the ITPR3 SNP rs2296336 was reported to be independent of SNP rs9272723, chosen as a proxy for the effect of the HLA DR-DQ locus, because it showed the highest T1D association in the (sparsely covered) HLA DR-DQ region. However, a biallelic marker may not fully reflect the multiallelic haplotypes that confer the strong T1D risk. In addition, given the strong geographic allele-frequency gradients at HLA, even within a single country, population stratification is an additional possible source of false positives.
In this study, we attempted to replicate this novel association with a family-based approach, which is immune to population stratification, with a more rigorous correction for LD with HLA class II.
Results and discussion
For the reported T1D association (odds ratio ¼ 1.8, minor allele frequency (MAF) ¼ 0.298) 1 , we had 495% statistical power to replicate the association. Instead, our family-based study (Table 1) actually found rs2296336 association with T1D but in the opposite direction; unlike the previous report 1 , the minor allele was protective in our study (note that as we tested the complementary strand, the minor allele C in our study is on the reverse strand of chromosome 6, and corresponds to the minor allele G on the forward strand in the previous report). The probability of such a discrepancy for samples obtained from the same population is 1.32 Â 10
À5
. Genotyping error seems unlikely, given the quality measures of our rs2296336 typing. No gender-specific effect or parent-of-origin effect was identified in our study.
The median age at onset of the T1D children in the Canadian cohort is 8 with the lower and upper quartiles at 4.6 and 11 years. The median age in the study by Roach et al.
1 was 13.8 years. To exclude the age-at-onset effect in the two populations causing the discrepancy between the two studies, we compared the T1D age-ofonset in patients with different rs2296336 genotypes. By the Mann-Whitney test, no age-of-onset difference among the three genotypes of rs2296336 was found either (Table 2) . Although the ITPR3 protein is involved in insulin and pancreatic exocrine secretion, 2, 3 it has no effect on the age at onset of T1D.
Because of the known extended LD at the MHC locus, LD between ITPR3 and HLA class II may be responsible for the T1D association. To address this possibility, we investigated the LD between rs2296336 and the HLA DQB1 alleles, using HLA-DQB1 genotypes that were available in 794 of the family trios. In this subset, association of T1D with the major allele G of rs2296336 is again seen and remains statistically significant (P ¼ 0.020), odds ratio (95% confidence interval) ¼ 1.21 (1.03, 1.41). On the basis of T1D association in our sample, the DQB1 alleles were classified into two groups, T1D predisposing (DQ*0201 and DQ*0302) and T1D protective (DQ*0301, DQ*0303, DQ*0304, DQ*0402, DQ*0501, DQ*0502, DQ*0503, DQ*0602, DQ*0603, and DQ*0604 (Table 3) . Weak but statistically significant LD was identified between rs2296336 and the two groups of DQB1 alleles (D' ¼ 0.083, P ¼ 0.022). The major allele G of rs2296336 is in LD with the predisposing DQB1 alleles, and the minor allele C of rs2296336 is in LD with the protective DQB1 alleles. Given the strong DR-DQ effect, 
Abbreviation: T1D, type 1 diabetes. The age-of-onset effect of rs2296336 in T1D patients was tested by the Mann-Whitney test. The genotypes of HLA-DQB1 were obtained by sequencing of the HLA-DQB1 exon 2 based on the reported method 6 with a small modification as described in our previous study 7 in a subset of 794 families. At the polymorphic site in the intron 1/exon 2 primer, a degenerate sense primer spanning the intron 1/exon 2 border, 5 0 -ATTCCYCGCAGAGGATTTCG-3 0 , was used. To identify the HLA-DQB1 alleles from the sequencing results, VBA scripts were written to align the sequence results with the allele sequences from the IMGT/HLA database 8 (http://www.ebi.ac.uk/imgt/HLA/index.html). The genotyping call rate was 94.1%, and the Mendelian error rate was 1.3%. The OR estimation and P-values for T1D association. The P values were not corrected for multiple comparisons, the significant level a ¼ 3.84 Â 10
À3
. We genotyped 1 120 European nuclear family trios with one T1D-affected offspring and two parents (3360 individuals). The samples were collected in pediatric diabetes clinics in Montreal, Toronto, Ottawa and Winnipeg. All patients were diagnosed under the age of 18, and were treated with insulin since diagnosis and none has stopped treatment for any reason. The Research Ethics Board of the Montreal Children's Hospital and other participating centers approved the study, and written informed consent was obtained from all patients. Genotypes for the ITPR3 SNP rs2296336 were obtained using the Sequenom iPLEX assay (Sequenom, Cambridge, MA, USA). The 90 CEU (European-descent individuals genotyped HapMap) were included as accuracy controls. The genotyping call rate for rs2296336 was 99.75%, and no Mendelian error was found. The genotypes in the parents were in Hardy-Weinberg equilibrium with P ¼ 0.410. The remaining SNPs in the panel were chosen to follow-up the first stage of a genome-wide association study 4 . The transmission disequilibrium test (TDT) and the conditional logistic regression analysis were done using the TDTPHASE program in the UNPHASED software (http://www.hgmp.mrc.ac.uk/Bfdudbrid/ software/unphased/). even weak LD with HLA-DQB1 can explain the T1D association that we observed. Indeed, regression analysis conditioned on the two types of DQB1 alleles in our dataset found no T1D association from the ITPR3 SNP rs2296336 (P ¼ 0.542).
In addition, we found that the ITPR3 SNP rs2296336 has different LD with two T1D predisposing DQB1 alleles. The predisposing allele G of rs2296336 is in significant LD with the DQ*0201 allele (D' ¼ 0.199, P ¼ 9.77 Â 10
À5
), but not DQ*0302 allele. On the contrary, the protective allele C of rs2296336 is in LD with the DQ*03 alleles (D' ¼ 0.059, P ¼ 0.035). The LD of rs2296336 with DQ*02 is significantly different from either the LD with DQ*0301 (P ¼ 0.004) or the LD with DQ*0302 (P ¼ 0.004). LD with DQ*02 vs DQ*03 could explain the T1D association that we further observed as DQ*0201 (99.8% of DQ*02) is highly predisposing, whereas of the two main alleles in DQ*03, DQ*0302 (58.8% of DQ*03) is predisposing and DQ*0301 (32.2% of DQ*03) is protective, thus diluting the effect. As Shown in our analysis, the combined T1D predisposing effect of DQ*0302 and DQ*0301 is smaller than DQ*0201. With DQ*0201 as the reference of 1, the relative risk (95% confidence interval) of the combined effect of DQ*0302 and DQ*0301 is 0.717 (0.589 and 0.873), P ¼ 8.84 Â 10
À4
, which can explain the minor allele C was protective in our study. Again, regression analysis conditioned on the DQ*02 and DQ*03 alleles in our dataset found no independent T1D association from the ITPR3 SNP rs2296336 (P ¼ 0.136). The discrepancy with the findings of Roach et al. 1 can be easily explained by the known variation in frequencies of DQ*02 and DQ*03 among European populations (http://www.allelefrequencies.net). In a population with higher DQ*02 frequency, the major G allele of rs2296336 may be found T1D predisposing. On the other hand, in a population with higher DQ*03 frequency, the minor C allele of rs2296336 may be found T1D predisposing.
In conclusion, our study does not support the ITPR3 SNP as a T1D locus. In contrast to the previous report 1 , our study detected a T1D association in the opposite direction in Canadians of mixed European descent, and found LD between the ITPR3 SNP rs2296336 and DQ*02, DQ*03 that can explain the association. The combined analysis of the study by Roach et al. 1 and our study using the Mantel-Haenszel method gives P ¼ 0.582. Therefore, our findings do not support an obvious role of genetic variation of the ITPR3 gene in T1D risk and highlight the importance of rigorous testing of all T1D associations in/near the extended MHC locus on Chr 6p21 for dependence on LD with specific alleles at the HLA class II genes, for which a single SNP cannot be a perfect proxy.
